Sage Therapeutics Inc Equity-NMS: SAGE

$- -7.37 (January 1, 1970)

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Error in Fetching Data, Please retry later.
Previous close :$7.37
Open :$7.28
Today's high :$7.31
Today's low :$7
52W low :$4.62
52W high :$17.045
EPS(TTM): :-6.59
Shares O/S :61.48 M
Market cap :430.37 M

Compare with Other Stocks

Stocks Price 1D PE Market Cap
Sage Therapeutics Inc $- -0.02% - 430.37M

Frequently Asked Questions

What is the share price of Sage Therapeutics Inc today?

Sage Therapeutics Inc (SAGE) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

About Sage Therapeutics Inc

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.